- Home
- OKYO vs RDI Comparison
OKYO vs RDI Comparison
Compare OKYO & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- RDI
- Stock Information
- Founded
- OKYO 2007
- RDI 1937
- Country
- OKYO United Kingdom
- RDI United States
- Employees
- OKYO N/A
- RDI N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- RDI Movies/Entertainment
- Sector
- OKYO Health Care
- RDI Consumer Discretionary
- Exchange
- OKYO Nasdaq
- RDI Nasdaq
- Market Cap
- OKYO 37.0M
- RDI 30.1M
- IPO Year
- OKYO 2022
- RDI N/A
- Fundamental
- Price
- OKYO $1.19
- RDI $1.42
- Analyst Decision
- OKYO Strong Buy
- RDI Hold
- Analyst Count
- OKYO 1
- RDI 1
- Target Price
- OKYO $7.00
- RDI $2.40
- AVG Volume (30 Days)
- OKYO 143.7K
- RDI 46.8K
- Earning Date
- OKYO 04-08-2025
- RDI 03-31-2025
- Dividend Yield
- OKYO N/A
- RDI N/A
- EPS Growth
- OKYO N/A
- RDI N/A
- EPS
- OKYO N/A
- RDI N/A
- Revenue
- OKYO N/A
- RDI $210,527,000.00
- Revenue This Year
- OKYO N/A
- RDI $16.31
- Revenue Next Year
- OKYO N/A
- RDI $6.78
- P/E Ratio
- OKYO N/A
- RDI N/A
- Revenue Growth
- OKYO N/A
- RDI N/A
- 52 Week Low
- OKYO $0.81
- RDI $1.22
- 52 Week High
- OKYO $1.74
- RDI $1.90
- Technical
- Relative Strength Index (RSI)
- OKYO 45.06
- RDI 50.20
- Support Level
- OKYO $1.31
- RDI $1.23
- Resistance Level
- OKYO $1.48
- RDI $1.46
- Average True Range (ATR)
- OKYO 0.11
- RDI 0.10
- MACD
- OKYO -0.03
- RDI 0.00
- Stochastic Oscillator
- OKYO 17.07
- RDI 45.71
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.